UA84881C2 - Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его - Google Patents

Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его

Info

Publication number: UA84881C2
Authority: UA; Ukraine
Prior art keywords: amorphous form; rapamycin; hydroxymethyl; hydroxy; ester
Prior art date: 2003-09-03

Application number

UAA200603517A

Other languages

English (en)

Ukrainian (uk)

Inventor

Эрик Дж. Бенджамин

Мухаммад Ашраф

Ашвінкумар Джаін

Original Assignee

Уайт

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2004-08-16

Publication date

2008-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA84881(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-16 Application filed by Уайт filed Critical Уайт

2008-12-10 Publication of UA84881C2 publication Critical patent/UA84881C2/ru

Links

PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

UAA200603517A 2003-09-03 2004-08-16 Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его UA84881C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US49978903P	2003-09-03	2003-09-03

Publications (1)

Publication Number	Publication Date
UA84881C2 true UA84881C2 (ru)	2008-12-10

Family

ID=34272870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200603517A UA84881C2 (ru)	2003-09-03	2004-08-16	Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его

Country Status (25)

Country	Link
US (2)	US7271177B2 (ru)
EP (1)	EP1660081A1 (ru)
JP (1)	JP2007504226A (ru)
KR (1)	KR20060090803A (ru)
CN (1)	CN1874771A (ru)
AR (1)	AR045559A1 (ru)
AU (1)	AU2004270154A1 (ru)
BR (1)	BRPI0414066A (ru)
CA (1)	CA2536775A1 (ru)
CO (1)	CO5680426A2 (ru)
CR (1)	CR8293A (ru)
EC (1)	ECSP066473A (ru)
GT (1)	GT200400175A (ru)
IL (1)	IL173786A0 (ru)
MX (1)	MXPA06002123A (ru)
NO (1)	NO20061048L (ru)
PA (1)	PA8611201A1 (ru)
PE (1)	PE20050945A1 (ru)
RU (1)	RU2345999C2 (ru)
SA (1)	SA04250334B1 (ru)
SG (1)	SG145716A1 (ru)
TW (1)	TW200510428A (ru)
UA (1)	UA84881C2 (ru)
WO (1)	WO2005023254A1 (ru)
ZA (1)	ZA200601822B (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2345999C2 (ru) *	2003-09-03	2009-02-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
JP2007517879A (ja) *	2004-01-08	2007-07-05	ワイス	Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
JP4224115B2 (ja)	2004-04-14	2009-02-12	ワイス	ラパマイシン４２−エステル誘導体の位置特異的合成
CA2562164A1 (en) *	2004-04-27	2005-11-10	Wyeth	Labeling of rapamycin using rapamycin-specific methylases
ATE483716T1 (de)	2004-08-27	2010-10-15	Cordis Corp	Lösungsmittelfreies amorphes rapamycin
US20060094744A1 (en) *	2004-09-29	2006-05-04	Maryanoff Cynthia A	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2595766A1 (en)	2005-02-09	2006-08-17	Wyeth	Cci-779 polymorph and use thereof
US7622578B2 (en) *	2005-12-07	2009-11-24	Wyeth	Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
AR058282A1 (es) *	2005-12-07	2008-01-30	Wyeth Corp	Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
BRPI0619592A2 (pt) *	2005-12-07	2016-09-06	Wyeth Corp	métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
WO2007072869A1 (ja) *	2005-12-21	2007-06-28	Eisai R & D Management Co., Ltd.	１，２－ジヒドロピリジン化合物の非晶質体
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414526B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414909B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080234657A1 (en) *	2007-03-22	2008-09-25	Medtronic Vascular, Inc.	Methods for contributing to cardiovascular treatments
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en)	2007-07-20	2014-10-07	Medtronic Vascular, Inc.	Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) *	2008-04-24	2009-10-29	Medtronic Vascular, Inc.	Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
EP2365802B1 (en)	2008-11-11	2017-08-02	The Board of Regents,The University of Texas System	Microcapsules of rapamycin and use for treating cancer
US20100227799A1 (en) *	2009-03-09	2010-09-09	Medtronic Vascular, Inc.	Simultaneous photodynamic therapy and photo induced polymerization
JP5637568B2 (ja) *	2009-05-12	2014-12-10	コーセプトセラピューティクス，インコーポレイテッド	固体形態および調製のためのプロセス
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US8829024B2 (en)	2011-01-07	2014-09-09	Corcept Therapeutics, Inc.	Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en)	2012-05-25	2014-10-14	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en)	2012-05-25	2025-02-18	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP2968281B1 (en)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
US9951009B2 (en) *	2013-08-29	2018-04-24	Cadila Healthcare Limited	Polymorphic form of pyrrole derivative and intermediate thereof
PL3848027T3 (pl)	2013-11-25	2023-07-24	Corcept Therapeutics Incorporated	Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
MX2019011543A (es)	2017-03-31	2019-12-16	Corcept Therapeutics Inc	Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
EP3848065B1 (en)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
PT115056B (pt) *	2018-10-04	2021-12-10	Hovione Farm Sa	Formas amorfas de agentes quelantes e seus métodos de preparação
EP3880266B1 (en)	2018-11-14	2025-05-07	Lutonix, Inc.	Medical device with drug-eluting coating on modified device surface
US11234971B2 (en)	2018-12-19	2022-02-01	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en)	2018-12-19	2022-07-19	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11464764B2 (en)	2018-12-19	2022-10-11	Corcept Therapeutics Incorporated	Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
JP7789561B2 (ja)	2019-02-22	2025-12-22	コーセプトセラピューティクス，インコーポレイテッド	レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
WO2020209828A1 (en)	2019-04-08	2020-10-15	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
JP7569492B2 (ja)	2019-12-11	2024-10-18	コーセプトセラピューティクス，インコーポレイテッド	抗精神病薬誘発性体重増加のミリコリラントによる治療方法
WO2021242912A1 (en)	2020-05-27	2021-12-02	Corcept Therapeutics Incorporated	Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
WO2022134033A1 (en)	2020-12-25	2022-06-30	Corcept Therapeutics Incorporated	Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR20250073629A (ko)	2022-10-06	2025-05-27	코어셉트 쎄라퓨틱스 인코포레이티드	글루코코르티코이드 수용체 조절제의 제형
US12433882B2 (en)	2022-10-28	2025-10-07	Corcept Therapeutics Incorporated	Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
EP0833828B1 (en) *	1995-06-09	2002-11-20	Novartis AG	Rapamycin derivatives
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) *	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US5989591A (en)	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
TWI256395B (en) *	1999-09-29	2006-06-11	Wyeth Corp	Regioselective synthesis of rapamycin derivatives
DE60324609D1 (de)	2002-09-17	2008-12-18	Wyeth Corp	GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
KR20060057605A (ko) *	2003-08-07	2006-05-26	와이어쓰	Ｃｃｉ-779의 위치선택적 합성 방법
RU2345999C2 (ru) *	2003-09-03	2009-02-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
JP2007517879A (ja)	2004-01-08	2007-07-05	ワイス	Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物

2004
- 2004-08-16 RU RU2006110568/04A patent/RU2345999C2/ru not_active IP Right Cessation
- 2004-08-16 JP JP2006525345A patent/JP2007504226A/ja not_active Withdrawn
- 2004-08-16 KR KR1020067004527A patent/KR20060090803A/ko not_active Abandoned
- 2004-08-16 WO PCT/US2004/026591 patent/WO2005023254A1/en not_active Ceased
- 2004-08-16 CA CA002536775A patent/CA2536775A1/en not_active Abandoned
- 2004-08-16 SG SG200805820-8A patent/SG145716A1/en unknown
- 2004-08-16 UA UAA200603517A patent/UA84881C2/ru unknown
- 2004-08-16 BR BRPI0414066-4A patent/BRPI0414066A/pt not_active IP Right Cessation
- 2004-08-16 CN CNA2004800325370A patent/CN1874771A/zh active Pending
- 2004-08-16 AU AU2004270154A patent/AU2004270154A1/en not_active Withdrawn
- 2004-08-16 EP EP04781305A patent/EP1660081A1/en not_active Withdrawn
- 2004-08-16 MX MXPA06002123A patent/MXPA06002123A/es active IP Right Grant
- 2004-08-31 US US10/930,487 patent/US7271177B2/en not_active Expired - Fee Related
- 2004-09-01 PE PE2004000844A patent/PE20050945A1/es not_active Application Discontinuation
- 2004-09-01 TW TW093126302A patent/TW200510428A/zh unknown
- 2004-09-02 AR ARP040103142A patent/AR045559A1/es unknown
- 2004-09-03 GT GT200400175A patent/GT200400175A/es unknown
- 2004-09-03 PA PA20048611201A patent/PA8611201A1/es unknown
- 2004-10-12 SA SA4250334A patent/SA04250334B1/ar unknown
2006
- 2006-02-16 IL IL173786A patent/IL173786A0/en unknown
- 2006-03-02 ZA ZA200601822A patent/ZA200601822B/xx unknown
- 2006-03-03 NO NO20061048A patent/NO20061048L/no not_active Application Discontinuation
- 2006-03-16 CR CR8293A patent/CR8293A/es not_active Application Discontinuation
- 2006-03-17 CO CO06027353A patent/CO5680426A2/es unknown
- 2006-04-03 EC EC2006006473A patent/ECSP066473A/es unknown
2007
- 2007-08-10 US US11/891,500 patent/US7446111B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ECSP066473A (es)	2006-10-10
MXPA06002123A (es)	2006-05-17
BRPI0414066A (pt)	2006-10-24
RU2006110568A (ru)	2007-10-10
AR045559A1 (es)	2005-11-02
SG145716A1 (en)	2008-09-29
NO20061048L (no)	2006-05-24
WO2005023254A1 (en)	2005-03-17
SA04250334B1 (ar)	2008-05-19
US20080070950A1 (en)	2008-03-20
CA2536775A1 (en)	2005-03-17
PE20050945A1 (es)	2005-12-14
ZA200601822B (en)	2008-12-31
US7446111B2 (en)	2008-11-04
EP1660081A1 (en)	2006-05-31
PA8611201A1 (es)	2005-05-10
AU2004270154A1 (en)	2005-03-17
CN1874771A (zh)	2006-12-06
TW200510428A (en)	2005-03-16
RU2345999C2 (ru)	2009-02-10
CR8293A (es)	2006-07-14
US20050049271A1 (en)	2005-03-03
KR20060090803A (ko)	2006-08-16
US7271177B2 (en)	2007-09-18
IL173786A0 (en)	2006-07-05
JP2007504226A (ja)	2007-03-01
CO5680426A2 (es)	2006-09-29
GT200400175A (es)	2005-04-18

Publication	Publication Date	Title
UA84881C2 (ru)	2008-12-10	Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
IL166824A0 (en)	2006-01-15	Oral formulations
NO20050455L (no)	2005-02-09	Parenterale formuleringer inneholdende en rapamycinhydroksyester
MX2007005221A (es)	2007-06-22	Formas cristalinas de ascomicina y preparacion de ellas.
TW200608973A (en)	2006-03-16	Rapamycin polymorph Ⅱ and uses thereof
MXPA05012025A (es)	2006-02-03	Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2005030144A3 (en)	2005-10-27	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2007044050A3 (en)	2007-06-14	1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
MX2009006885A (es)	2009-08-28	Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
FR2860224B1 (fr)	2006-06-02	Solide cristallise im-12 et son procede de preparation
WO2004087073A3 (en)	2005-11-03	Treatment of demyelinating conditions
EP1969940A3 (en)	2008-12-10	Nematicidal compositions
BRPI0509660A (pt)	2007-10-09	compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
CL2007002988A1 (es)	2008-01-18	Proceso para la preparacion de un isomero individual de rapamicina 42 ester con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) monopegilado.
MXPA05009934A (es)	2006-03-21	Composiciones farmaceuticas que comprenden una combinacion de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunologicamente mediadas.
GB0512099D0 (en)	2005-07-20	Compounds
SG152296A1 (en)	2009-05-29	Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
UA83697C2 (ru)	2008-08-11	Cci-779 для лечения лимфомы из мантийных клеток
WO2008057511A3 (en)	2008-07-03	Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
TW200732342A (en)	2007-09-01	Process for the preparation of purified crystalline CCI-779
HK1085935A (en)	2006-09-08	Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same